Pharmstandard

JSC Pharmstandard
Type	Private
Industry	Pharmaceuticals
Founded	2003
Headquarters	Dolgoprudny, Russia
Area served	Worldwide
Key people	Viktor Vladimirovich Kharitonin,(Chairman) ; Igor Konstantinovich Krylov, (CEO)
Products	Remedies
Revenue	$638 million[1] (2017)
Operating income	$231 million[2] (2016)
Net income	$119 million[2] (2016)
Total assets	$1.41 billion[2] (2016)
Total equity	$936 million[2] (2016)
Number of employees	6,450[3] (2015)
Website	pharmstd.com

JSC Pharmstandard (Russian: ПАО "Фармстандарт", romanized: PAO "Farmstandart") is a Russian multinational[4] pharmaceutical company.[5] It is headquartered in Dolgoprudny, Moscow Oblast.

Pharmstandard's makes and exports over 400 generic and proprietary drugs, including products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc.

The company has six manufacturing facilities located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk and Tyumen.

History

Pharmstandard was established in 2003 as a result of a merger.[5]

In May 2007 the company raised $880 million in an IPO, valuing the company at $2.2 billion.[6] Roman Abramovich owned a 17% stake in the company until March 2008.[7]

In 2013 the company announced plans to buy the ingredient supplier Bever Pharmaceutical, causing Pharmstandard shares to fall 25%.[8]

Pharmstandard was delisted from the London and Moscow stock exchanges in 2017.[9][10]

References

"Рейтинг крупнейших компаний России по объему реализации продукции". Expert RA. Archived from the original on 28 October 2018. Retrieved 28 October 2018.
http://pharmstd.com/news3files/2016ifrsresults.pdf.
http://www.rbc.ru/companies/id/126.
Pharmstandard International
Anatoly, Zhuplev (2014). Geo-Regional Competitiveness in Central and Eastern Europe, the Baltic Countries, and Russia. IGI Global. p. 228. ISBN 9781466660557.
Spikes, Salamander Davoudiand Sarah (5 May 2007). "Russian drug IPO raises $880m". Financial Times. Retrieved 25 September 2017.
"Russia's Abramovich sells his stake in drug maker". Reuters. 2008. Retrieved 25 September 2017.
"Pharmstandard to buy ingredient supplier for $590 million". Reuters. 2013. Retrieved 25 September 2017.
"BRIEF-Pharmstandard shares to be delisted as of March 24 - Moscow Exchange". Reuters. 17 February 2017. Retrieved 23 April 2017.
"Об исключении ценных бумаг из Списка ценных бумаг, допущенных к торгам, и о прекращении торгов ценными бумагами". Московская Биржа. Retrieved 28 August 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[wikidata-6c0709bb7e5042292b6473f81e1f08a3a138ad95-v3-1] "Рейтинг крупнейших компаний России по объему реализации продукции". Expert RA. Archived from the original on 28 October 2018. Retrieved 28 October 2018.

[wikidata-5cdc80e369f44355a65e8c8b3a6dd7198fe167bc-v3-2] ttp://pharmstd.com/news3files/2016ifrsresults.pdf.

[wikidata-a1bc1a8f93c25de40787809834db55f8793de1ef-v3-3] ttp://www.rbc.ru/companies/id/126.

[4] Pharmstandard International

[zhuplev14-5] Anatoly, Zhuplev (2014). Geo-Regional Competitiveness in Central and Eastern Europe, the Baltic Countries, and Russia. IGI Global. p. 228. ISBN 9781466660557.

[6] Spikes, Salamander Davoudiand Sarah (5 May 2007). "Russian drug IPO raises $880m". Financial Times. Retrieved 25 September 2017.

[uful-7] "Russia's Abramovich sells his stake in drug maker". Reuters. 2008. Retrieved 25 September 2017.

[8] "Pharmstandard to buy ingredient supplier for $590 million". Reuters. 2013. Retrieved 25 September 2017.

[9] "BRIEF-Pharmstandard shares to be delisted as of March 24 - Moscow Exchange". Reuters. 17 February 2017. Retrieved 23 April 2017.

[10] "Об исключении ценных бумаг из Списка ценных бумаг, допущенных к торгам, и о прекращении торгов ценными бумагами". Московская Биржа. Retrieved 28 August 2017.